PDF herunterladen
Semin Reprod Med 2008; 26(1): 039-044
DOI: 10.1055/s-2007-992923
© Thieme Medical Publishers

Cardiovascular Disease Risk Factors in Polycystic Ovary Syndrome

Anuja Dokras1
  • 1Department of Obstetrics and Gynecology, University of Iowa, Iowa City, Iowa; Current affiliation: Penn Fertility Care, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
08. Januar 2008 (online)

    Lizenzen und Reprints

ABSTRACT

Polycystic ovary syndrome (PCOS) is a common endocrinopathy associated with an increasing number of cardiovascular comorbidities. The relationship between insulin resistance and PCOS was described more than 3 decades ago. Women with PCOS also have an increased prevalence of several established cardiovascular risk factors such as diabetes, hypertension, and dyslipidemia. These factors contribute to the increased risk of endothelial dysfunction, increased carotid artery intima media thickness, and coronary artery calcification noted in women with PCOS compared with controls. Although truncal obesity is very prevalent in PCOS, these surrogate markers of atherosclerosis have been shown to be independent of body weight in young, asymptomatic subjects. Metabolic syndrome is a cluster of risk factors that also confer an increased risk of cardiovascular disease. Women with PCOS have also been shown to have a significantly higher prevalence of metabolic syndrome compared with age-matched controls. Currently, there are no longitudinal studies confirming increased cardiovascular morbidity and/or mortality in women with PCOS. However, the early presence of traditional and other cardiovascular risk factors underscores the need to screen and aggressively counsel and treat these women to prevent future symptomatic cardiovascular disease.

KEYWORDS

Cardiovascular disease - metabolic syndrome - diabetes - hypertension

REFERENCES

  • 1 Knochenhauser E S, Key T J, Kahser-Miller M, Waggoner W, Boots L R, Aziz R. Prevalence of polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study.  J Clin Endocrinol Metab. 1998;  83 3078-3082
    CrossrefPubMedGoogle Scholar
  • 2 Dunaif A, Givens J R, Haseltine F P, Merriam G R. Current Issues in Endocrinology and Metabolism, Polycystic Ovary Syndrome. Boston, MA; Blackwell Scientific 1992
  • 3 The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.  Fertil Steril. 2004;  81 19-25
    PubMedGoogle Scholar
  • 4 Dahlgren E, Janson P O, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction-evaluated from a risk factor model based on a prospective study of women.  Acta Obstet Gynecol Scand. 1992;  71 599-604
    CrossrefPubMedGoogle Scholar
  • 5 Legro R S, Kunselman A R, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome.  Am J Med. 2001;  111 607-613
    CrossrefPubMedGoogle Scholar
  • 6 Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia D H. Screening women with polycystic ovary syndrome for metabolic syndrome.  Obstet Gynecol. 2005;  106 131-137
    Google Scholar
  • 7 Legro R S, Kunselman A R, Dodson W C, Dunaif A. Prevalence and predictors of risk for type II diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective controlled study in 254 affected women.  J Clin Endocrinol Metab. 1999;  84 165-169
    CrossrefPubMedGoogle Scholar
  • 8 Heron M P, Smith B L. Deaths: leading causes for 2003.  Natl Vital Stat Rep. 2007;  55 1-92
    PubMedGoogle Scholar
  • 9 Birdsall M A, Farquhar C M, White H D. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization.  Ann Intern Med. 1997;  126 32-35
    CrossrefPubMedGoogle Scholar
  • 10 Solomon C G, Hu F B, Dunaif A et al.. Menstrual cycle irregularity and risk for future cardiovascular disease.  J Clin Endocrinol Metab. 2002;  87 2013-2017
    CrossrefPubMedGoogle Scholar
  • 11 Lo J C, Feigenbaum S L, Yang J, Pressman A R, Selby J V, Go A S. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome.  J Clin Endocrinol Metab. 2006;  91 1357-1363
    CrossrefPubMedGoogle Scholar
  • 12 Ehrmann D A, Kasza K, Azziz R, Legro R S, Ghazzi M N. for the PCOS/Troglitazone Study Group . Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2005;  90 66-71
    Google Scholar
  • 13 Legro R S, Gnatuk C L, Kunselman A R, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study.  J Clin Endocrinol Metab. 2005;  90 3236-3242
    CrossrefPubMedGoogle Scholar
  • 14 Palmert M R, Gordon C M, Kartashov A I, Legro R S, Emans S J, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2002;  87 1017-1023
    CrossrefPubMedGoogle Scholar
  • 15 Wild R A, Painter P C, Coulson P B, Carruth K B, Ranney G B. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 1985;  61 946-951
    CrossrefPubMedGoogle Scholar
  • 16 Gaziano J M, Hennekens C H, O'Donnell C J, Breslow J L, Buring J E. Fasting triblycerides, high-density lipoprotein, and risk of myocardial infarction.  Circulation. 1997;  96 2520-2525
    CrossrefPubMedGoogle Scholar
  • 17 Maruyama C, Imamura K, Teramoto T. Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia.  J Atheroscler Thromb. 2003;  10 186-191
    PubMedGoogle Scholar
  • 18 McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers identify overweight individuals who are insulin-resistant.  Ann Intern Med. 2003;  139 802-809
    PubMedGoogle Scholar
  • 19 Brehm A, Pfeiler G, Pacini G, Vierhapper H, Roden M. Relationship between serum lipoprotein ratios and insulin resistance in obesity.  Clin Chem. 2004;  50 2316-2322
    CrossrefPubMedGoogle Scholar
  • 20 McLaughlin T, Reaven G, Abbasi F et al.. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?.  Am J Cardiol. 2005;  96 399-404
    CrossrefPubMedGoogle Scholar
  • 21 Chobanian A V, Bakris G L, Black H R for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure et al. National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report.  JAMA. 2003;  289 2560-2572
    CrossrefPubMedGoogle Scholar
  • 22 Holte J, Gennarelli G, Berne C, Bergh T, Lithell H. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state?.  Hum Reprod. 1996;  11 23-28
    PubMedGoogle Scholar
  • 23 Chen M J, Yang W S, Yang J H, Chen C L, Ho H N, Yang Y S. Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome.  Hypertension. 2007;  49 1442-1447
    CrossrefPubMedGoogle Scholar
  • 24 Haffner S M, Valdez R A, Hazuda H P, Mitchell B D, Morales P A, Stern M P. Prospective analysis of the insulin-resistance syndrome (syndrome X).  Diabetes. 1992;  41 715-722
    PubMedGoogle Scholar
  • 25 National Institutes of Health .Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication 01-3670. Bethesda, MD; National Institutes of Health 2001
    Google Scholar
  • 26 Grundy S M, Cleeman J I, Daniels S R et al.. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, Blood Institute Scientific Statement.  Circulation. 2005;  112 2735-2752
    CrossrefPubMedGoogle Scholar
  • 27 Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women.  Arch Intern Med. 2004;  164 1066-1076
    CrossrefPubMedGoogle Scholar
  • 28 Talbott E O, Zborowski J V, Rager J R, Boudreaux M Y, Edmundowicz D A, Guzick D S. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2004;  89 5454-5461
    CrossrefPubMedGoogle Scholar
  • 29 Ehrmann D A, Liljenquist D R, Kasza K, Azziz R, Legro R S, Ghazzi M N. for the PCOS/Troglitazone Study Group . Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2006;  91 48-53
    CrossrefPubMedGoogle Scholar
  • 30 Ford E S, Giles W H, Dietz W H. Prevalence of metabolic syndrome among US adults.  JAMA. 2002;  287 356-359
    CrossrefPubMedGoogle Scholar
  • 31 Perticone F, Ceravolo R, Pujia A et al.. Prognostic significance of endothelial dysfunction in hypertensive patients.  Circulation. 2001;  104 191-196
    PubMedGoogle Scholar
  • 32 Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease.  Circulation. 2001;  104 2673-2678
    CrossrefPubMedGoogle Scholar
  • 33 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's.  Nature. 1993;  362 801-809
    CrossrefPubMedGoogle Scholar
  • 34 Steinberg H O, Chaker H, Leaming R, Johnson A, Brechtel G, Baron A D. Obesity/insulin resistance is associated with endothelial dysfunction - implications for the development of insulin resistance.  J Clin Invest. 1996;  97 2601-2610
    CrossrefPubMedGoogle Scholar
  • 35 Orio Jr F, Palomba S, Cascella T et al.. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2004;  89 4588-4593
    CrossrefPubMedGoogle Scholar
  • 36 Tarkun I, Arslan B C, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation.  J Clin Endocrinol Metab. 2004;  89 5592-5596
    CrossrefPubMedGoogle Scholar
  • 37 Dokras A, Jagasia D H, Maifeld M, Sinkey C A, VanVoorhis B J, Haynes W G. Obesity/insulin resistance but not hyperandrogenism is an important mediator of vascular dysfunction in women with PCOS.  Fertil Steril. 2006;  86 1702-1709
    CrossrefPubMedGoogle Scholar
  • 38 Paradisi G, Steinberg H O, Hempfling A et al.. Polycystic ovary syndrome is associated with endothelial dysfunction.  Circulation. 2001;  103 1410-1415
    CrossrefPubMedGoogle Scholar
  • 39 Mather K J, Verma S, Corenblum B, Anderson T J. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome.  J Clin Endocrinol Metab. 2000;  85 1851-1856
    CrossrefPubMedGoogle Scholar
  • 40 Bickerton A ST, Clark N, Meeking D et al.. Cardiovascular risk in women with polycystic ovary syndrome (PCOS).  J Clin Pathol.. 2005;  58 151-154
    CrossrefPubMedGoogle Scholar
  • 41 Bots M L, Baldassarre D, Simon A et al.. Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations?.  Eur Heart J. 2007;  28 398-406
    CrossrefPubMedGoogle Scholar
  • 42 Talbott E O, Guzick D S, Sutton-Tyrell K et al.. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women.  Arterioscler Thromb Vasc Biol. 2000;  20 2414-2421
    PubMedGoogle Scholar
  • 43 Carmina E, Orio F, Palomba S et al.. Endothelial dysfunction in PCOS: role of obesity and adipose hormones.  Am J Med. 2006;  119 356.e1-6
    PubMedGoogle Scholar
  • 44 Talbott E O, Zborowski J V, Boudreaux M Y, McHugh-Pemu K P, Sutton-Tyrrell K, Guzick D S. The relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2004;  89 6061-6067
    CrossrefPubMedGoogle Scholar
  • 45 Agatston A S, Janowitz W R, Hildner F J, Zusmer N R, Viamonte M, Detrano R. Quantification of coronary calcium using ultrafast computed tomography.  J Am Coll Cardiol. 1990;  15 827-832
    CrossrefPubMedGoogle Scholar
  • 46 Arad Y, Spadaro L A, Goodman K, Newstein D, Guerci A D. Prediction of coronary events with electron beam computed tomography.  J Am Coll Cardiol. 2000;  36 1253-1260
    CrossrefPubMedGoogle Scholar
  • 47 Christian R C, Dumesic D A, Behrenbeck T, Oberg A L, Sheedy II P F, Fitzpatrick L A. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2003;  88 2562-2568
    CrossrefPubMedGoogle Scholar
  • 48 Shroff R, Kirschner A, Maifeld M, Van Beek E, Jagasia D, Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis.  J Clin Endocrinol Metab. 2007 Sep 11;  , [Epub ahead of print]
    PubMedGoogle Scholar
  • 49 Mahoney L T, Burns T L, Stanford W et al.. Coronary risk factors measured in childhood and young adult life are associated with coronary artery calcification in young adults: the Muscatine Study.  J Am Coll Cardiol. 1996;  27 277-284
    PubMedGoogle Scholar
  • 50 Tsimikas S, Willerson J T, Ridker P M. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients.  J Am Coll Cardiol. 2006;  47 C19-C31
    CrossrefPubMedGoogle Scholar
  • 51 Kelly C C, Lyall H, Petrie J R, Gould G W, Connell J M, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome.  J Clin Endocrinol Metab. 2001;  86 2453-2455
    CrossrefPubMedGoogle Scholar
  • 52 Weisberg S P, McCann D, Desai M, Rosenbaum M, Leibel R L, Ferrante Jr A W. Obesity is associated with macrophage accumulation in adipose tissue.  J Clin Invest. 2003;  112 1796-1808
    CrossrefPubMedGoogle Scholar
  • 53 Mohlig M, Spranger J, Osterhoff M et al.. The polycystic ovary syndrome per se is not associated with increased chronic inflammation.  Eur J Endocrinol. 2004;  150 525-532
    CrossrefPubMedGoogle Scholar
  • 54 Boulman N, Levy Y, Leiba R et al.. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease.  J Clin Endocrinol Metab. 2004;  89 2160-2165
    CrossrefPubMedGoogle Scholar
  • 55 Puder J J, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance.  J Clin Endocrinol Metab. 2005;  90 6014-6021
    CrossrefPubMedGoogle Scholar
  • 56 Olszanecka-Glinianowicz M, Banas M, Zahorska-Markiewicz B et al.. Is the polycystic ovary syndrome associated with chronic inflammation per se?.  Eur J Obstet Gynecol Reprod Biol. 2007;  133 197-202
    CrossrefPubMedGoogle Scholar
  • 57 Vgontzas A N, Trakada G, Bixler E O et al.. Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea.  Metabolism. 2006;  55 1076-1082
    CrossrefPubMedGoogle Scholar
  • 58 Farrell S W, Cheng Y J, Blair S N. Prevalence of the metabolic syndrome across cardiorespiratory fitness levels in women.  Obes Res. 2004;  12 824-830
    CrossrefPubMedGoogle Scholar

Anuja DokrasM.D. 

Associate Professor, Penn Fertility Care, University of Pennsylvania Medical Center

3701 Market St., Suite 800, Philadelphia, PA 19104

eMail: ADokras@obgyn.upenn.edu